Drug Trial Radar · NCT06905522
A PAN-USR TB Multi-Center Trial
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
610
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Jan 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shenzhen Third People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Affiliated Hospital of Zhejiang University; Beijing Chest Hospital, Capital Medical University; Shenyang Tenth People's Hospital; The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region; The Fourth Hospital of Inner Mongolia Autonomous Region; Guizhou Aerospace Hospital
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-TB is an innovative concept in TB treatment, aiming to develop a universal regimen effective for all forms of active TB, including both drug-susceptible and drug-resistant strains. The primary goal of the PAN-TB regimen is to simplify the treatment process, reduce costs, and improve treatment success rates. The ideal Target Regimen Profile (TRP) for PAN-TB includes superior efficacy compared to standard treatment for non-drug-resistant TB, a reduced treatment duration from the current 4-6 months to 2-3 months, and improved safety and tolerability. This project aims to explore a new ultra-short-course treatment regimen for both drug-sensitive (DS-TB) and drug-resistant TB (MDR/RR-TB), which aligns with the latest trends in TB treatment both domestically and internationally. The regimen also has significant practical implications for enhancing treatment efficacy and reducing patient burden. Furthermore, the study will explore the identification of new biomarkers closely linked to treatment outcomes over the course of full-cycle therapy.
Conditions
- Pulmonary Tuberculosis
Interventions
Bedaquiline (B)Drug
The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
Sitafloxacin (S)Drug
200mg once daily
Linezolid (L)Drug
600mg once daily
Pyrazinamide (Z)Drug
20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
Isoniazid (H)Drug
4-6 mg/kg once daily, 300 mg once daily
Rifampicin (R)Drug
8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
Ethambutol (E)Drug
15-25 mg/kg once daily, 750 mg once daily
Moxifloxacin (M)Drug
400mg once daily
Pretomanid (Pa)Drug
200mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Unfavorable outcomesTime frame: 12 months (52 weeks)
- SafetyTime frame: 2 months (9 weeks)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital of Capital Medical University
Beijing, China · Recruiting
Shenzhen Third People's Hospital
Shenzhen, China · Recruiting
The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region
Ürümqi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.